Highlights from the perspectives in melanoma XII conference

Pigment Cell and Melanoma Research

Volumn 22, Issue 2, 2009, Pages 156-165

  Kirkwood, John M ^a   Eggermont, Alexander ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AS 15; ASO 2B; BMS 663513; CANCER ANTIBODY; CARBOPLATIN; CD40 ANTIBODY AGONIST; CP 870893; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IPILIMUMAB; MDX 1106; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; PACLITAXEL; PEGINTERFERON; PROTEIN NODAL; SERUM AMYLOID A; SORAFENIB; TEMOZOLOMIDE; TICILIMUMAB; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; APOPTOSIS; ARM; ARTHROPATHY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CHILL; COLITIS; CONFERENCE PAPER; DENDRITIC CELL; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; EMBRYONIC STEM CELL; ENDOCRINE DISEASE; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; HEAD; HUMAN; HUMAN PITUITARY TUMOR TRANSFORMING GENE 1; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; LEG; LIVER TOXICITY; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MICROENVIRONMENT; NECK; NETHERLANDS; NONHUMAN; ONCOGENE; PATHOGENESIS; PROGNOSIS; PROTEOMICS; PRURITUS; RASH; RIGOR; SENTINEL LYMPH NODE; SIDE EFFECT; SKIN PIGMENTATION; SKIN TOXICITY; SUN TANNING; SUNBURN; THYROTROPIN BLOOD LEVEL; TRAVEL; TRUNK; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; ICELAND; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING; SUNBATHING;

EID: 62249156198     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00555.x     Document Type: Conference Paper

References (48)

1. van Akkooi, A.C., de Wilt, J.H., Verhoef, C. et al. (2006a). High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur. J. Cancer 42, 372 380.
2. van Akkooi, A.C., de Wilt, J.H., Verhoef, C. et al. (2006b). Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann. Oncol. 17, 1578 1585.
3. van Akkooi, A.C., Nowecki, Z.I., Voit, C., Schäfer-Hesterberg, G., Michej, W., de Wilt, J.H., Rutkowski, P., Verhoef, C. Eggermont, A.M. (2008a). Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients. A multicenter study in 388 SN positive patients. Ann. Surg. 248, 949 955.
4. van Akkooi, A.C., de Wilt, J.H., Verhoef, C. Eggermont, A.M. (2008b). The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor? J. Clin. Oncol. 26, 6011.
5. Apetoh, L., Ghiringhelli, F., Tesniere, A. et al. (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47 59.
6. Apetoh, L., Ghiringhelli, F., Tesniere, A. et al. (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050 1059.
7. Apetoh, L., Tesniere, A., Ghiringhelli, F., Kroemer, G. Zitvogel, L. (2008). Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 68, 4026 4030.
8. Brahmer, J., Topalian, S., Wollner, I. et al. (2008). Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol. 26, 3006.
9. Chin, K., Ibrahim, R., Berman, D. et al. (2008) Treatment Guidlines for the Management of Immune-Related Adverse Events in Patients Treated With Ipilimumab, an Anti-CTLA-4 Therapy. Poster presented at: 33rd ESMO Congress; 12-16 September, Stockholm, Sweden.
10. Curtin, J.A., Busam, K., Pinkel, D. Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340 4346.
11. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
12. Diehl, L., den Boer, A.T., Schoenberger, S.P. et al. (1999). CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5, 774 779.
13. Diffey, B. (2007). Sunbeds, beauty and melanoma. Br. J. Dermatol. 157, 215 216.
14. Eggermont, A.M.M., Suciu, S., MacKie, R. et al. for the EORTC Melanoma Group. (2005). Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366, 1189 1196.
15. Eggermont, A.M., Suciu, S., Santinami, M. et al. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372, 117 126.
16. El Shamy, W.M. Livingston, D.M. (2004). Identification of BRCA1-IRIS, a BRCA1 locus product. Nat. Cell Biol. 6, 954 967.
17. Essner, R. Kojima, M. (2002). Dendritic cell function in sentinel nodes. Oncology (Williston Park) 16, 27 31.
18. Findeisen, P., Zapatka, M., Peccerella, T. et al. (in press). Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol., in press.
19. Fong, L. Small, E.J. (2008). Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275 5283.
20. Gonzalez, M.A., Tachibana, K.E., Laskey, R.A. Coleman, N. (2005). Control of DNA replication and its potential clinical exploitation. Nat. Rev. Cancer 5, 135 141.
21. de Gruijl, T.D., Sombroek, C.C., Lougheed, S.M. et al. (2006). A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J. Immunol. 176, 7232 7242.
22. Hauschild, A., Engel, G., Brenner, W. et al. (1999). Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br. J. Dermatol. 140, 1065 1071.
23. Hendrix, M.J., Seftor, E.A., Seftor, R.E., Kasemeier-Kulesa, J., Kulesa, P.M. Postovit, L.M. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer. 7, 246 255.
24. Hersey, P. (2006). Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr. Opin. Oncol. 18, 189 196.
25. Hocker, T.L., Singh, M.K. Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol. 128, 2575 2595.
26. International Agency for Research on Cancer Working Group on artificial ultraviolent (UV) light and skin cancer 2007). The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cancer. 120 : 1116 1112.
27. Lee, J.H., Torisu-Itakara, H., Cochran, A.J. et al. (2005). Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11, 107 112.
28. Li, B., Lalani, A.S., Harding, T.C. et al. (2006). Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808 6816.
29. McGovern, V.J., Mihm Jr., M.C., Bailly, C. et al. (1973). The classification of malignant melanoma and its histologic reporting. Cancer 32, 1446 1457.
30. Mian, S., Ugurel, S., Parkinson, E. et al. (2005). Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 23, 5088 5093.
31. Molenkamp, B.G., Vuylsteke, R.J., van Leeuwen, P.A. et al. (2005). Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am. J. Pathol. 167, 1301 1307.
32. Molenkamp, B.G., van Leeuwen, P.A., Meijer, S. et al. (2007). Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 13, 2961 2969.
33. Molenkamp, B.G., Sluijter, B.J., van Leeuwen, P.A. et al. (2008). Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin. Cancer Res. 14, 4532 4542.
34. O'Day, S., Gonzalez, R., Weber, R.W. et al. (2007). Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. J. Clin. Oncol. 25 (Suppl 18 8528.
35. Postovit, L.M., Seftor, E.A., Seftor, R.E. Hendrix, M.J. (2006). A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells 24, 501 505.
36. Quezada, S.A., Peggs, K.S., Curran, M.A. Allison, J.P. (2006). CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935 1945.
37. Rafnsson, V., Hrafnkelsson, J., Tulinius, H., Sigurgeirsson, B. Olafsson, J.H. (2004). Risk factors for malignant melanoma in an Icelandic population sample. Prev. Med. 39, 247 252.
38. Sotomayor, E.M., Borrello, I., Tubb, E. et al. (1999). Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780 787.
39. Spatz, A., Giglia-Mari, G., Benhamou, S. Sarasin, A. (2001). Association between DNA repair-deficiency and high level of p53 mutations in melanoma of Xeroderma pigmentosum2. Cancer Res. 61, 2480 2486.
40. Sznol, M., Hodi, F., Margolin, K. et al. (2008). Phase I study BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol. 26, 3007.
41. Thomas, J.M. (2008). Prognostic false-positivity of the sentinel node in melanoma. Nat. Clin. Pract. Oncol. 5, 18 23 Review et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105, 3041 3046.
42. Viros, A., Fridlyand, J., Bauer, J. et al. (2008). Improving melanoma classification by integrating genetic and morphologic features1. PLoS Med. 5, e120.
43. Vonderheide, R.H., Flaherty, K.T., Khalil, M. et al. (2007). Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876 883.
44. Vuylsteke, R.J., Molenkamp, B.G., Gietema, H.A. et al. (2004). Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 64, 8456 8460.
45. Vuylsteke, R.J., Molenkamp, B.G., van Leeuwen, P.A. et al. (2006). Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin. Cancer Res. 12, 2826 2833.
46. Winnepenninckx, V., Lazar, V., Michiels, S. et al. (2006a). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 98, 472 482.
47. Winnepenninckx, V., biec-Rychter, M., Belien, J.A. et al. (2006b). Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Mod. Pathol. 19, 1170 1180.
48. Yuan, J., Gnjatic, S., Li, H. et al. (2008). CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U.S.A. 105, 20410 20415.